Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Merck Sharp & Dohme LLC
Lisata Therapeutics, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.
Leaf Vertical Inc.
Galectin Therapeutics Inc.